These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34958928)

  • 1. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
    Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
    J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    Hong MH; Choi YJ; Ahn HK; Lim SM; Keam B; Kim DW; Kim TM; Youk J; Kim YJ; Hwang S; Kim S; Kim JW; Kim HR; Kang JH
    JAMA Oncol; 2024 Oct; 10(10):1342-1351. PubMed ID: 39145962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
    Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
    Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
    Han JY; Ahn MJ; Lee KH; Lee YG; Kim DW; Min YJ; Kim SW; Cho EK; Kim JH; Lee GW; Lee SS; Lee NM; Jang HW; Han H; Park H; Lee J; Cho BC
    BMC Med; 2024 Oct; 22(1):428. PubMed ID: 39379931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.
    Kim H; Ahn BC; Lee J; Lee JB; Hong MH; Kim HR; Cho BC; Lim SM
    Lung Cancer; 2023 Jun; 180():107213. PubMed ID: 37104879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
    Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
    J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
    Lee B; Ji W; Lee JC; Song SY; Shin YS; Cho YH; Park JE; Park H; Choi CM
    Thorac Cancer; 2023 Aug; 14(22):2233-2237. PubMed ID: 37365915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
    Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control.
    Jeon HL; Kwak M; Kim S; Yu HY; Shin JY; Jung HA
    Sci Rep; 2024 Jun; 14(1):14659. PubMed ID: 38918528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
    Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lazertinib: First Approval.
    Dhillon S
    Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
    Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
    J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
    Lee KH; Cho BC; Ahn MJ; Lee YG; Lee Y; Lee JS; Kim JH; Min YJ; Lee GW; Lee SS; Lee KH; Ko YH; Shim BY; Kim SW; Shin SW; Choi JH; Kim DW; Cho EK; Park KU; Kim JS; Chun SH; Wang J; Choi S; Kang JH
    Cancer Res Treat; 2024 Jan; 56(1):48-60. PubMed ID: 37402411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
    Soo RA; Cho BC; Kim JH; Ahn MJ; Lee KH; Zimina A; Orlov S; Bondarenko I; Lee YG; Lim YN; Lee SS; Lee KH; Pang YK; Fong CH; Kang JH; Lim CS; Danchaivijitr P; Kilickap S; Yang JC; Arslan C; Lee H; Park SN; Cicin I
    J Thorac Oncol; 2023 Dec; 18(12):1756-1766. PubMed ID: 37865896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
    Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
    J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.